John J Park

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 2

Top Topics

Decision Making

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

He-Rui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Min-Hee Ryu, John J Park, Jee Hyun Kim, Yahua Zhong, Yiming Zhao, Mark Voskoboynik, Yongmei Yin, Kan Liu, Andreas Kaubisch, Caigang Liu, Jian Zhang, Shouman Wang, Seock-Ah Im, Vinod Ganju, Minal Barve, Hui Li, Changsheng Ye, Amitesh C Roy, Li-Yuan Bai, Chia-Jui Yen, Shanzhi Gu, Yung-Chang Lin, Ling-Ying Wu, Lequn Bao, Kaijing Zhao, Yu Shen, Shangyi Rong, Xiaoyu Zhu, Erwei Song
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Ines Pires daSilva, Tasnia Ahmed, Jennifer Leigh McQuade, Caroline A Nebhan, John J Park, Judith M Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K Oberoi, Selma Ugurel, Lauren E Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L Smith, Richard A Scolyer, Ana M Arance, Lisa Pickering, James M G Larkin, Paul C Lorigan, Christian U Blank, Dirk Schadendorf, Michael A Davies, Matteo S Carlino, Douglas B Johnson, Georgina V Long, Serigne N Lô, Alexander M Menzies
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (10) (2022)